OS Therapies Incorporated
OSTX
$1.74
-$0.05-2.79%
AMEX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -11.75% | 2.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.18% | 74.25% | |||
| Operating Income | 15.18% | -74.25% | |||
| Income Before Tax | 22.76% | -95.67% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 22.76% | -95.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 22.76% | -95.67% | |||
| EBIT | 15.18% | -74.25% | |||
| EBITDA | 15.34% | -75.63% | |||
| EPS Basic | 30.42% | -79.42% | |||
| Normalized Basic EPS | 30.43% | -79.55% | |||
| EPS Diluted | 30.42% | -79.42% | |||
| Normalized Diluted EPS | 30.43% | -79.55% | |||
| Average Basic Shares Outstanding | 11.00% | 9.03% | |||
| Average Diluted Shares Outstanding | 11.00% | 9.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||